Simcere Pharmaceutical Group Limited (HKG:2096)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
13.49
-0.12 (-0.88%)
At close: Dec 5, 2025
82.79%
Market Cap 35.02B
Revenue (ttm) 7.79B
Net Income (ttm) 964.48M
Shares Out 2.60B
EPS (ttm) 0.39
PE Ratio 34.39
Forward PE 24.55
Dividend 0.18 (1.29%)
Ex-Dividend Date Jun 18, 2025
Volume 5,834,000
Average Volume 7,880,797
Open 13.56
Previous Close 13.61
Day's Range 13.16 - 13.61
52-Week Range 6.20 - 15.08
Beta 0.99
RSI 52.12
Earnings Date Nov 14, 2025

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW... [Read more]

Sector Healthcare
Founded 1995
Employees 6,584
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2096
Full Company Profile

Financial Performance

In 2024, HKG:2096's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.